Literature DB >> 14971051

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

Jörg Vollmer1, Risini Weeratna, Paul Payette, Marion Jurk, Christian Schetter, Meike Laucht, Tanja Wader, Sibylle Tluk, Ming Liu, Heather L Davis, Arthur M Krieg.   

Abstract

Oligodeoxynucleotides (ODN) with unmethylated deoxycytidyl-deoxyguanosine (CpG) dinucleotides (CpG ODN) mimic the immunostimulatory activity of bacterial DNA and are recognized by the Toll-like receptor 9 (TLR9). CpG ODN of the B-Class stimulate strong B cell and NK cell activation and cytokine production. The highest degrees of NK stimulation as well as IFN-alpha secretion by plasmacytoid DC were found to occur only with A-Class ODN. A third class of CpG ODN combines the immune effects of A- and B-Class CpG ODN. C-Class ODN strongly stimulate B cell or NK cell activation and IFN-alpha production. In contrast to the A-Class, the C-Class is wholly phosphorothioate, has no poly-G stretches, but has palindromic sequences combined with stimulatory CpG motifs. All classes stimulate TLR9-dependent signaling, but with strikingly different dose-response relationships that are quite in contrast to those observed for IFN-alpha. Effects similar to those on human cells were observed on mouse splenocytes. In contrast, splenocytes from TLR9-deficient mice did not show any response to the three CpG ODN classes. In vivo studies demonstrate that C-Class ODN are very potent Th1 adjuvants. C-Class ODN may represent new therapeutic drugs that combine the effects of A- and B-Class ODN for broad applications in infectious disease or cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14971051     DOI: 10.1002/eji.200324032

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  187 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.

Authors:  Jörg Vollmer; Robert Rankin; Hanna Hartmann; Marion Jurk; Ulrike Samulowitz; Tanja Wader; Andrea Janosch; Christian Schetter; Arthur M Krieg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

4.  Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.

Authors:  Folkert Steinhagen; Corinna Meyer; Debra Tross; Mayda Gursel; Takahiro Maeda; Sven Klaschik; Dennis M Klinman
Journal:  J Leukoc Biol       Date:  2012-07-02       Impact factor: 4.962

Review 5.  Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.

Authors:  Benjamin G Keselowsky; Chang Qing Xia; Michael Clare-Salzler
Journal:  Hum Vaccin       Date:  2011-01-01

6.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

7.  Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice.

Authors:  Mike Kulis; Balachandra Gorentla; A Wesley Burks; Xiao-Ping Zhong
Journal:  Mol Nutr Food Res       Date:  2013-02-05       Impact factor: 5.914

Review 8.  Trafficking of endosomal Toll-like receptors.

Authors:  Bettina L Lee; Gregory M Barton
Journal:  Trends Cell Biol       Date:  2014-01-15       Impact factor: 20.808

9.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

10.  Leukemia-derived exosomes and cytokines pave the way for entry into the brain.

Authors:  Ichiko Kinjyo; Denis Bragin; Rachel Grattan; Stuart S Winter; Bridget S Wilson
Journal:  J Leukoc Biol       Date:  2019-01-31       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.